SARS-CoV-2原型株无症状感染对Omicron株BA.1、BA.2与BA.5的保护概率

郑楠; 陈鑫华; 陆婉莹; 余宏杰

doi:10.16462/j.cnki.zhjbkz.2023.02.007

SARS-CoV-2原型株无症状感染对Omicron株BA.1、BA.2与BA.5的保护概率

doi: 10.16462/j.cnki.zhjbkz.2023.02.007

200032 上海，复旦大学公共卫生学院流行病学教研室，公共卫生安全教育部重点实验室

基金项目:

国家自然科学基金 82130093

详细信息

通讯作者:
余宏杰，E-mail：yhj@fudan.edu

中图分类号: R183
计量
- 文章访问数: 210
- HTML全文浏览量: 155
- PDF下载量: 129
- 被引次数: 0
出版历程
- 收稿日期: 2022-12-25
- 修回日期: 2023-01-13
- 网络出版日期: 2023-02-20
- 刊出日期: 2023-02-10

Protection probability against SARS-CoV-2 Omicron variant BA.1, BA.2 and BA.5 in asymptomatic infection caused by prototype strain

Key Laboratory of Public Health Safety of Ministry of Education, Department of Epidemiology, School of Public Health, Fudan University, Shanghai 200032, China

Funds:

National Natural Science Foundation of China 82130093

More Information

Corresponding author: YU Hong-jie, E-mail: yhj@fudan.edu

摘要

摘要: 目的评估SARS-CoV-2原型株无症状感染后对奥密克戎株(B.1.1.529，Omicron)BA.1、BA.2与BA.5感染、有症状感染和重症感染的保护概率。方法基于前期研究得到的无症状感染原型株者中和抗体动态曲线，利用logistic回归的预测模型估计无症状感染者在确诊后28 d、51 d和261 d对Omicron株BA.1、BA.2和BA.5感染所致的感染、有症状感染、重症三种结局的保护概率。结果 SARS-CoV-2原型株无症状感染者在确诊后28 d，对Omicron株BA.1、BA.2和BA.5再感染的保护概率分别为30%(95% CI：16%~52%)、23%(95% CI：15%~36%)和8%(95% CI：4%~16%)，到261 d分别降至9%(95% CI：3%~21%)、6%(95% CI：3%~12%)和2%(95% CI：1%~4%)；确诊后28 d，对Omicron株BA.1、BA.2和BA.5有症状感染的保护概率分别为51%(95% CI：28%~80%)、42%(95% CI：26%~67%)和16%(95% CI：7%~40%)，到261 d分别降至16%(95% CI：7%~35%)、12%(95% CI：7%~22%)和3%(95% CI：1%~8%)；确诊后28 d对Omicron株BA.1、BA.2和BA.5感染所致的重症结局的保护概率分别为91%(95% CI：72%~98%)、88%(95% CI：70%~97%)和66%(95% CI：35%~90%)，到261 d分别降至60%(95% CI：35%~86%)、51%(95% CI：32%~75%)和22%(95% CI：10%~50%)。结论 SARS-CoV-2原型株无症状感染者体内的中和抗体对Omicron株BA.5的保护概率低于BA.1和BA.2，对重症结局的保护效果较好，有症状感染次之，对感染的保护效果较差。
- 新型冠状病毒 /
- 无症状感染 /
- Omicron株BA.1 /
- Omicron株BA.2 /
- Omicron株BA.5 /
- 中和抗体 /
- 保护概率
Abstract: Objective To estimate the protection probability against SARS-CoV-2 variant Omicron strains BA.1, BA.2 and BA.5 infection, symptomatic infection and severe disease outcomes in asymptomatic individuals infected with SARS-CoV-2 prototype strain previously. Methods Our previous study had shown that the dynamic change of neutralizing antibodies in asymptomatic individuals infected with the SARS-CoV-2 prototype strain. Based on our previous study, a peer-reviewed predictive model on the basis of logistic model was used to estimate the protection probability of asymptomatic individuals against Omicron strains BA.1, BA.2 and BA.5. We estimate the protection probability against infection, symptomatic infection and severe disease outcomes on 28, 51 and 261 days after confirmation. Results The protection probability against reinfection of Omicron variant strains BA.1, BA.2, and BA.5 on 28 days after confirmation were 30% (95% CI: 16%-52%), 23% (95% CI: 15%-36%) and 8% (95% CI: 4%-16%) respectively, while decreased to 9% (95% CI: 3%-21%), 6% (95% CI: 3%-12%) and 2% (95% CI: 1%-4%) on 261 days after confirmation. The protection probability against symptomatic infection of Omicron strains BA.1, BA.2, and BA.5 were 51% (95% CI: 28%-80%), 42% (95% CI: 26%-67%) and 16% (95% CI: 7%-40%) respectively on 28 days after confirmation, while decreased to 16% (95% CI: 7%-35%), 12% (95% CI: 7%-22%) and 3% (95% CI: 1%-8%) on 261 days after confirmation. The protection probability against severe disease of Omicron strains BA.1, BA.2, and BA.5 were 91% (95% CI: 72%-98%), 88% (95% CI: 70%-97%) and 66% (95% CI: 35%-90%) respectively on 28 days after confirmation, while decreased to 60% (95% CI: 35%-86%), 51% (95% CI: 32%-75%) and 22% (95% CI: 10%-50%) on 261 days after confirmation. Conclusions Neutralizing antibodies induced in asymptomatic individuals infected with prototype strain could provide higher protection against Omicron strain BA.5 than Omicron strains BA.1 and BA.2. Among the three clinical outcomes, the protective probability against severe disease outcome was better, followed by symptomatic infection, and the protective probability against infection was poor.
- SARS-CoV-2 /
- Asymptomatic infection /
- Omicron BA.1 /
- Omicron BA.2 /
- Omicron BA.5 /
- Neutralizing antibody /
- Protection probability

HTML全文

图 1 SARS-CoV-2原型株无症状感染者对Omicron株BA.1、BA.2与BA.5的保护概率

Figure 1. Protection probability against Omicron BA.1, BA.2 and BA.5 in asymptomatic individuals infected with SARS-CoV-2 prototype strain

下载: 全尺寸图片幻灯片

参考文献(30)

[1]	World Health Organization. Coronavirus disease (COVID-19) pandemic[EB/OL]. (2022-12-11)[2022-12-19]. https://www.who.int/emergencies/diseases/novel-coronavirus-2019.
[2]	Plante JA, Mitchell BM, Plante KS, et al. The variant gambit: COVID-19's next move[J]. Cell Host Microbe, 2021, 29(4): 508-515. DOI: 10.1016/j.chom.2021.02.020.
[3]	World Health Organization. Tracking SARS-CoV-2 variants[EB/OL]. (2023-01-13)[2023-01-16]. https://www.who.int/activities/tracking-SARS-CoV-2-variants.
[4]	Evans JP, Zeng C, Qu PK, et al. Neutralization of SARS-CoV-2 Omicron sub-lineages BA. 1, BA. 1.1, and BA. 2[J]. Cell Host Microbe, 2022, 30(8): 1093-1102. e3. DOI: 10.1016/j.chom.2022.04.014.
[5]	Ai JW, Wang X, He XY, et al. Antibody evasion of SARS-CoV-2 Omicron BA. 1, BA. 1.1, BA. 2, and BA. 3 sub-lineages[J]. Cell Host Microbe, 2022, 30(8): 1077-1083. e4. DOI: 10.1016/j.chom.2022.05.001.
[6]	Lyngse FP, Kirkeby CT, Denwood M, et al. Transmission of SARS-CoV-2 Omicron VOC subvariants BA. 1 and BA. 2: Evidence from Danish Households[J]. medRxiv, 2022, 13(1): 5760. DOI: 10.1101/2022.01.28.22270044.
[7]	Stegger M, Edslev SM, Sieber RN, et al. Occurrence and significance of Omicron BA. 1 infection followed by BA. 2 reinfection[J/OL]. medRxiv, 2022. DOI: 10.1101/2022.02.19.22271112.
[8]	Tuekprakhon A, Nutalai R, Dijokaite-Guraliuc A, et al. Antibody escape of SARS-CoV-2 Omicron BA. 4 and BA. 5 from vaccine and BA. 1 serum[J]. Cell, 2022, 185(14): 2422-2433. e13. DOI: 10.1016/j.cell.2022.06.005.
[9]	Cao YL, Yisimayi A, Jian FC, et al. BA. 2.12.1, BA. 4 and BA. 5 escape antibodies elicited by Omicron infection[J]. Nature, 2022, 608(7923): 593-602. DOI: 10.1038/s41586-022-04980-y.
[10]	Meyerowitz EA, Richterman A, Bogoch Ⅱ, et al. Towards an accurate and systematic characterisation of persistently asymptomatic infection with SARS-CoV-2[J]. Lancet Infect Dis, 2021, 21(6): e163-e169. DOI: 10.1016/s1473-3099(20)30837-9.
[11]	Chen XH, Chen ZX, Azman AS, et al. Serological evidence of human infection with SARS-CoV-2: a systematic review and meta-analysis[J]. Lancet Glob Health, 2021, 9(5): e598-e609. DOI: 10.1016/s2214-109x(21)00026-7.
[12]	Chen XH, Yan XM, Sun KY, et al. Estimation of disease burden and clinical severity of COVID-19 caused by Omicron BA. 2 in Shanghai, February-June 2022[J]. Emerg Microbes Infect, 2022, 11(1): 2800-2807. DOI: 10.1080/22221751.2128435.
[13]	Gruell H, Vanshylla K, Weber T, et al. Antibody-mediated neutralization of SARS-CoV-2[J]. Immunity, 2022, 55(6): 925-944. DOI: 10.1016/j.immuni.2022.05.005.
[14]	Khanolkar A. Elucidating T Cell and B Cell Responses to SARS-CoV-2 in Humans: Gaining Insights into Protective Immunity and Immunopathology[J]. Cells, 2021, 11(1): 67. DOI: 10.3390/cells11010067.
[15]	Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection[J]. Nat Med, 2021, 27(7): 1205-1211. DOI: 10.1038/s41591-021-01377-8.
[16]	Pilz S, Theiler-Schwetz V, Trummer C, et al. SARS-CoV-2 reinfections: Overview of efficacy and duration of natural and hybrid immunity[J]. Environ Res, 2022, 209: 112911. DOI: 10.1016/j.envres.2022.112911.
[17]	Altarawneh HN, Chemaitelly H, Tang P, et al. Protection afforded by prior infection against SARS-CoV-2 reinfection with the Omicron variant[J/OL]. medRxiv, 2022. DOI: 10.1101/2022.01.05.22268782.
[18]	Lu WY, Zheng N, Chen XH, et al. Long-term neutralizing antibody dynamics against SARS-CoV-2 in symptomatic and asymptomatic infections: a systematic review and meta-analysis[J/OL]. medRxiv, 2022. DOI: 10.1101/2022.12.15.22283503.
[19]	Chen XH, Wang W, Chen XH, et al. Prediction of long-term kinetics of vaccine-elicited neutralizing antibody and time-varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint[J]. BMC Med, 2022, 20(1): 36. DOI: 10.1186/s12916-022-02249-9.
[20]	Zou J, Xia HJ, Xie XP, et al. Neutralization against Omicron SARS-CoV-2 from previous non-Omicron infection[J]. Nat Commun, 2022, 13(1): 852. DOI: 10.1038/s41467-022-28544-w.
[21]	Cheng SM, Mok CKP, Chan KC, et al. SARS-CoV-2 Omicron variant BA. 2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022[J]. Euro Surveill, 2022, 27(18): 2200178. DOI: 10.2807/1560-7917.Es.2022.27.18.2200178.
[22]	Cheng SS, Mok CK, Li JK, et al. Plaque-neutralizing antibody to BA. 2.12.1, BA. 4 and BA. 5 in individuals with three doses of BioNTech or CoronaVac vaccines, natural infection and breakthrough infection[J]. J Clin Virol, 2022, 156: 105273. DOI: 10.1016/j.jcv.2022.105273.
[23]	Goldberg Y, Mandel M, Bar-On YM, et al. Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2[J]. N Engl J Med, 2022, 386(23): 2201-2212. DOI: 10.1056/NEJMoa2118946.
[24]	Andeweg SP, De Gier B, Eggink D, et al. Protection of COVID-19 vaccination and previous infection against Omicron BA. 1, BA. 2 and Delta SARS-CoV-2 infections[J]. Nat Commun, 2022, 13(1): 4738. DOI: 10.1038/s41467-022-31838-8.
[25]	Altarawneh HN, Chemaitelly H, Ayoub HH, et al. Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections[J]. N Engl J Med, 2022, 387(1): 21-34. DOI: 10.1056/NEJMoa2203965.
[26]	Altarawneh HN, Chemaitelly H, Ayoub HH, et al. Protective Effect of Previous SARS-CoV-2 Infection against Omicron BA. 4 and BA. 5 Subvariants[J]. N Engl J Med, 2022, 387(17): 1620-1622. DOI: 10.1056/NEJMc2209306.
[27]	Lau EHY, Tsang OTY, Hui DSC, et al. Neutralizing antibody titres in SARS-CoV-2 infections[J]. Nat Commun, 2021, 12(1): 63. DOI: 10.1038/s41467-020-20247-4.
[28]	Yu JY, Collier AY, Rowe M, et al. Neutralization of the SARS-CoV-2 Omicron BA. 1 and BA. 2 Variants[J]. N Engl J Med, 2022, 386(16): 1579-1580. DOI: 10.1056/NEJMc2201849.
[29]	Chemaitelly H, Ayoub HH, Almukdad S, et al. Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA. 1 and BA. 2 subvariants in Qatar[J]. Nat Commun, 2022, 13(1): 3082. DOI: 10.1038/s41467-022-30895-3.
[30]	Collie S, Nayager J, Bamford L, et al. Effectiveness and Durability of the BNT162b2 Vaccine against Omicron Sublineages in South Africa[J]. N Engl J Med, 2022, 387(14): 1332-1333. DOI: 10.1056/NEJMc2210093.